Helicobacter Pylori Infections – Pipeline Review, H1 2012
Helicobacter Pylori Infections – Pipeline Review, H1 2012
Summary
Global Markets Direct’s, 'Helicobacter Pylori Infections - Pipeline Review, H1 2012', provides an overview of the Helicobacter Pylori Infections therapeutic pipeline. This report provides information on the therapeutic development for Helicobacter Pylori Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Helicobacter Pylori Infections. 'Helicobacter Pylori Infections - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
Summary
Global Markets Direct’s, 'Helicobacter Pylori Infections - Pipeline Review, H1 2012', provides an overview of the Helicobacter Pylori Infections therapeutic pipeline. This report provides information on the therapeutic development for Helicobacter Pylori Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Helicobacter Pylori Infections. 'Helicobacter Pylori Infections - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- A snapshot of the global therapeutic scenario for Helicobacter Pylori Infections.
- A review of the Helicobacter Pylori Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Helicobacter Pylori Infections pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
- Identify and understand important and diverse types of therapeutics under development for Helicobacter Pylori Infections.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Helicobacter Pylori Infections pipeline depth and focus of Helicobacter Pylori Infections therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Contents
IntroductionGlobal Markets Direct Report Coverage
Helicobacter Pylori Infections Overview
Therapeutics Development
An Overview of Pipeline Products for Helicobacter Pylori Infections
Helicobacter Pylori Infections Therapeutics under Development by Companies
Helicobacter Pylori Infections Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Helicobacter Pylori Infections Therapeutics – Products under Development by Companies
Helicobacter Pylori Infections Therapeutics – Products under Investigation by Universities/Institutes
Companies Involved in Helicobacter Pylori Infections Therapeutics Development
Affinium Pharmaceuticals, Inc.
Deva Holding A.S.
EastPharma Ltd.
MerLion Pharmaceuticals Pte Ltd
EpiVax, Inc.
Vecta Ltd.
Helicobacter Pylori Infections – Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
AVEC - Drug Profile
Rifalazil - Drug Profile
H.Pylori Vaccine - Drug Profile
Lansoprazole + Amoxicillin + Clarithromycin + Metronidazole - Drug Profile
GT08 - Drug Profile
Levofloxacin + Amoxicillin + Lansoprazole - Drug Profile
Finafloxacin Oral - Drug Profile
NCA 600 mg - Drug Profile
Amoxicillin + Metronidazole + Omeprazole + Bismuth + Protexin Protect - Drug Profile
Nigella Sativa Seeds + Omeprazole - Drug Profile
Clarithromycin + Amoxicillin + Omeprazole - Drug Profile
Omeprazole + Amoxicillin + Azithromycin - Drug Profile
Omeprazole+ Amoxycilin + Clarithromycin - Drug Profile
Metronidazole + Amoxicillin + Bismuth + Omeprazole - Drug Profile
Sitafloxacin - Drug Profile
RHB 105 - Drug Profile
Fabl Inhibitor Program - Drug Profile
Levofloxacin + Amoxicillin + Lansoprazole - Drug Profile
Helicobacter Pylori Infections Therapeutics – Drug Profile Updates
Helicobacter Pylori Infections Therapeutics - Dormant Products
Helicobacter Pylori Infections – Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products Under Development for Helicobacter Pylori Infections, H1 2012
Products under Development for Helicobacter Pylori Infections – Comparative Analysis, H1 2012
Number of Products under Development by Companies, H1 2012
Number of Products under Investigation by Universities/Institutes, H1 2012
Comparative Analysis by Late Stage Development, H1 2012
Comparative Analysis by Mid Clinical Stage Development, H1 2012
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2012
Products under Development by Companies, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
Affinium Pharmaceuticals, Inc., H1 2012
Deva Holding A.S., H1 2012
EastPharma Ltd., H1 2012
MerLion Pharmaceuticals Pte Ltd, H1 2012
EpiVax, Inc., H1 2012
Vecta Ltd., H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Combination Products, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Molecule Type, H1 2012
Helicobacter Pylori Infections Therapeutics – Drug Profile Updates
Helicobacter Pylori Infections Therapeutics – Dormant Products
Helicobacter Pylori Infections Therapeutics – Dormant Products (Contd..1)
LIST OF FIGURES
Number of Products under Development for Helicobacter Pylori Infections, H1 2012
Products under Development for Helicobacter Pylori Infections – Comparative Analysis, H1 2012
Products under Development by Companies, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
Late Stage Products, H1 2012
Mid Clinical Stage Products, H1 2012
Discovery and Pre-Clinical Stage Products, H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Combination Products, H1 2012
Assessment by Route of Administration, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Molecule Type, H1 2012
Assessment by Stage and Molecule Type, H1 2012 Skip to top